Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01653418 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01653418 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT01653418, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
BEAM regimen (BCNU, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for relapsed/refractory lymphoma patients needing autologous stem cell transplantation. Since these components are all effective in myeloma and bortezomib has shown promising results in the transplant setting, here the investigators propose a phase II study to investigate the combination of bortezomib and BEAM as a new conditioning regimen for patients who relapse or progress after the first autologous transplantation and for whom a second autologous transplant is considered.
Interventions
- DRUG Melphalan
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Carmustine
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01653418
The ClinicalTrials.gov registry entry for NCT01653418 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT01653418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01653418 about?
NCT01653418 is a clinical study titled "Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation". BEAM regimen (BCNU, etoposide, cytarabine, and melphalan) is the most commonly used conditioning regimen for relapsed/refractory lymphoma patients needing autologous stem cell transplantation. Since these components are all effective in myeloma and bortezomib has shown promising results in the trans...
What is the current status of trial NCT01653418?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2012-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01653418?
The interventions under investigation include: Melphalan (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01653418?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.